Eosinophilic bioactivities in severe asthma

Tara F. Carr, Sergejs Berdnikovs, Hans Uwe Simon, Bruce Scott Bochner, Lanny J. Rosenwasser

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.

Original languageEnglish (US)
Article number112
JournalWorld Allergy Organization Journal
Volume9
Issue number1
DOIs
StatePublished - Jun 27 2016

Fingerprint

Eosinophils
Asthma
Eosinophilia
Biomarkers
Cytokines
Adaptive Immunity
Chemokines
Innate Immunity
Intercellular Signaling Peptides and Proteins
Monoclonal Antibodies
Guidelines
Lipids
Lung

Keywords

  • Bioactivities
  • Biotherapeutics
  • Eosinophilia
  • Eosinophils
  • Severe asthma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

Carr, Tara F. ; Berdnikovs, Sergejs ; Simon, Hans Uwe ; Bochner, Bruce Scott ; Rosenwasser, Lanny J. / Eosinophilic bioactivities in severe asthma. In: World Allergy Organization Journal. 2016 ; Vol. 9, No. 1.
@article{159c7abc8b2340ce8593fefe4f0cc6b6,
title = "Eosinophilic bioactivities in severe asthma",
abstract = "Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.",
keywords = "Bioactivities, Biotherapeutics, Eosinophilia, Eosinophils, Severe asthma",
author = "Carr, {Tara F.} and Sergejs Berdnikovs and Simon, {Hans Uwe} and Bochner, {Bruce Scott} and Rosenwasser, {Lanny J.}",
year = "2016",
month = "6",
day = "27",
doi = "10.1186/s40413-016-0112-5",
language = "English (US)",
volume = "9",
journal = "World Allergy Organization Journal",
issn = "1939-4551",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Eosinophilic bioactivities in severe asthma. / Carr, Tara F.; Berdnikovs, Sergejs; Simon, Hans Uwe; Bochner, Bruce Scott; Rosenwasser, Lanny J.

In: World Allergy Organization Journal, Vol. 9, No. 1, 112, 27.06.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Eosinophilic bioactivities in severe asthma

AU - Carr, Tara F.

AU - Berdnikovs, Sergejs

AU - Simon, Hans Uwe

AU - Bochner, Bruce Scott

AU - Rosenwasser, Lanny J.

PY - 2016/6/27

Y1 - 2016/6/27

N2 - Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.

AB - Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.

KW - Bioactivities

KW - Biotherapeutics

KW - Eosinophilia

KW - Eosinophils

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=84976585029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976585029&partnerID=8YFLogxK

U2 - 10.1186/s40413-016-0112-5

DO - 10.1186/s40413-016-0112-5

M3 - Review article

VL - 9

JO - World Allergy Organization Journal

JF - World Allergy Organization Journal

SN - 1939-4551

IS - 1

M1 - 112

ER -